Toxic shock syndrome secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]

Toxic shock syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Toxic Shock Syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Toxic shock syndrome secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Toxic shock syndrome secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Toxic shock syndrome secondary prevention
CDC on Toxic shock syndrome secondary prevention
Toxic shock syndrome secondary prevention in the news
Blogs on Toxic shock syndrome secondary prevention
Directions to Hospitals Treating Toxic shock syndrome
Risk calculators and risk factors for Toxic shock syndrome secondary prevention

Overview:

Secondary prevention strategies following toxic shock syndrome (TSS) include chemoprophylaxis for invasive group A streptococcus or staphylococcus carriers. Although it is still not certain to be helpful.

Secondary Prevention

One of the major complications of toxic shock syndrome is that it increase the risk of disease re-currency. This condition may be controlled by chemoprophylaxis of patients with a past medical history of TSS. However, there are limited data concerning chemoprophylaxis for severe invasive group A streptococcal or staphylococcal infections.

Several antibiotic regimens have been successful in eradicating group A streptococcus from the pharynx of chronic carriers (i.e., rifampin plus intramuscular benzathine penicillin or a 10-day course of a second-generation cephalosporin or clindamycin).